Special Issue

Lung Cancer—Advances in Therapy and Prognostic Prediction

Message from the Guest Editors

We are pleased to announce an upcoming Special Issue dedicated to the rapidly evolving landscape of lung cancer, with a focus on the rapeutic advancements and prognostic prediction. This Issue will highlight innovative, biomarker-driven treatment strategies including targeted therapies, immunotherapy combinations, and precision medicine approaches that integrate molecular profiling to guide individualized care. Emphasis will be placed on studies that advance our understanding of how genomic, transcriptomic, and liquid biopsy-based biomarkers can inform treatment selection, monitor disease progression, and refine prognostic models. As lung cancer care becomes increasingly personalized, this Special Issue aims to feature multidisciplinary research that reflects the shift toward precision oncology. We invite researchers, clinicians, and thought leaders to contribute original research articles, reviews, and commentaries that will define the next chapter in therapeutic advancements in lung cancer.

Guest Editors

Dr. Chinmay T. Jani

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA

Dr. Estelamari Rodríguez

Division of Medical Oncology, Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA

Deadline for manuscript submissions

28 February 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/242465

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

